356 related articles for article (PubMed ID: 23820017)
1. BreastMark: an integrated approach to mining publicly available transcriptomic datasets relating to breast cancer outcome.
Madden SF; Clarke C; Gaule P; Aherne ST; O'Donovan N; Clynes M; Crown J; Gallagher WM
Breast Cancer Res; 2013; 15(4):R52. PubMed ID: 23820017
[TBL] [Abstract][Full Text] [Related]
2. miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients.
Lánczky A; Nagy Á; Bottai G; Munkácsy G; Szabó A; Santarpia L; Győrffy B
Breast Cancer Res Treat; 2016 Dec; 160(3):439-446. PubMed ID: 27744485
[TBL] [Abstract][Full Text] [Related]
3. M1 Polarization Markers Are Upregulated in Basal-Like Breast Cancer Molecular Subtype and Associated With Favorable Patient Outcome.
Hachim MY; Hachim IY; Talaat IM; Yakout NM; Hamoudi R
Front Immunol; 2020; 11():560074. PubMed ID: 33304345
[TBL] [Abstract][Full Text] [Related]
4. Expression of micrornas in molecular genetic breast cancer subtypes.
Kolesnikov NN; Veryaskina YA; Titov SE; Rodionov VV; Gening TP; Abakumova TV; Kometova VV; Torosyan MK; Zhimulev IF
Cancer Treat Res Commun; 2019; 20():100026. PubMed ID: 31255253
[TBL] [Abstract][Full Text] [Related]
5. Integrated analysis of mRNA and miRNA profiles revealed the role of miR-193 and miR-210 as potential regulatory biomarkers in different molecular subtypes of breast cancer.
Evangelista AF; Oliveira RJ; O Silva VA; D C Vieira RA; Reis RM; C Marques MM
BMC Cancer; 2021 Jan; 21(1):76. PubMed ID: 33461524
[TBL] [Abstract][Full Text] [Related]
6. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
7. OvMark: a user-friendly system for the identification of prognostic biomarkers in publically available ovarian cancer gene expression datasets.
Madden SF; Clarke C; Stordal B; Carey MS; Broaddus R; Gallagher WM; Crown J; Mills GB; Hennessy BT
Mol Cancer; 2014 Oct; 13():241. PubMed ID: 25344116
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast Cancer.
Gong C; Tan W; Chen K; You N; Zhu S; Liang G; Xie X; Li Q; Zeng Y; Ouyang N; Li Z; Zeng M; Zhuang S; Lau WY; Liu Q; Yin D; Wang X; Su F; Song E
EBioMedicine; 2016 Sep; 11():199-209. PubMed ID: 27566954
[TBL] [Abstract][Full Text] [Related]
9. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis.
Harnan S; Tappenden P; Cooper K; Stevens J; Bessey A; Rafia R; Ward S; Wong R; Stein RC; Brown J
Health Technol Assess; 2019 Jun; 23(30):1-328. PubMed ID: 31264581
[TBL] [Abstract][Full Text] [Related]
10. A novel MAPK-microRNA signature is predictive of hormone-therapy resistance and poor outcome in ER-positive breast cancer.
Miller PC; Clarke J; Koru-Sengul T; Brinkman J; El-Ashry D
Clin Cancer Res; 2015 Jan; 21(2):373-85. PubMed ID: 25370469
[TBL] [Abstract][Full Text] [Related]
11. Inferred miRNA activity identifies miRNA-mediated regulatory networks underlying multiple cancers.
Lee E; Ito K; Zhao Y; Schadt EE; Irie HY; Zhu J
Bioinformatics; 2016 Jan; 32(1):96-105. PubMed ID: 26358730
[TBL] [Abstract][Full Text] [Related]
12. A 4-microRNA signature predicts lymph node metastasis and prognosis in breast cancer.
Chen X; Wang YW; Zhu WJ; Li Y; Liu L; Yin G; Gao P
Hum Pathol; 2018 Jun; 76():122-132. PubMed ID: 29555574
[TBL] [Abstract][Full Text] [Related]
13. Novel Predictors of Breast Cancer Survival Derived from miRNA Activity Analysis.
Aushev VN; Lee E; Zhu J; Gopalakrishnan K; Li Q; Teitelbaum SL; Wetmur J; Degli Esposti D; Hernandez-Vargas H; Herceg Z; Parada H; Santella RM; Gammon MD; Chen J
Clin Cancer Res; 2018 Feb; 24(3):581-591. PubMed ID: 29138345
[No Abstract] [Full Text] [Related]
14. The Discovery of Novel Biomarkers Improves Breast Cancer Intrinsic Subtype Prediction and Reconciles the Labels in the METABRIC Data Set.
Milioli HH; Vimieiro R; Riveros C; Tishchenko I; Berretta R; Moscato P
PLoS One; 2015; 10(7):e0129711. PubMed ID: 26132585
[TBL] [Abstract][Full Text] [Related]
15. Transcriptomics-based screening of molecular signatures associated with patients overall survival and their key regulators in subtypes of breast cancer.
Eskandari E; Motalebzadeh J
Cancer Genet; 2019 Nov; 239():62-74. PubMed ID: 31569063
[TBL] [Abstract][Full Text] [Related]
16. Is gene array testing to be considered routine now?
Paik S
Breast; 2011 Oct; 20 Suppl 3():S87-91. PubMed ID: 22015300
[TBL] [Abstract][Full Text] [Related]
17. Expression Pattern and Prognostic Value of EPHA/EFNA in Breast Cancer by Bioinformatics Analysis: Revealing Its Importance in Chemotherapy.
Liang Z; Wang X; Dong K; Li X; Qin C; Zhou H
Biomed Res Int; 2021; 2021():5575704. PubMed ID: 33977106
[TBL] [Abstract][Full Text] [Related]
18. Characterization of molecular scores and gene expression signatures in primary breast cancer, local recurrences and brain metastases.
Bustamante Eduardo M; Popovici V; Imboden S; Aebi S; Ballabio N; Altermatt HJ; Günthert A; Jaggi R
BMC Cancer; 2019 Jun; 19(1):549. PubMed ID: 31174485
[TBL] [Abstract][Full Text] [Related]
19. Mixture classification model based on clinical markers for breast cancer prognosis.
Zeng T; Liu J
Artif Intell Med; 2010; 48(2-3):129-37. PubMed ID: 20005686
[TBL] [Abstract][Full Text] [Related]
20. A three-gene model to robustly identify breast cancer molecular subtypes.
Haibe-Kains B; Desmedt C; Loi S; Culhane AC; Bontempi G; Quackenbush J; Sotiriou C
J Natl Cancer Inst; 2012 Feb; 104(4):311-25. PubMed ID: 22262870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
